Sina Vatandoust MD PhD

Associate Professor Flinders Centre for Innovation in Cancer, Medical Oncologist, Colorectal cancer, Breast Cancer,

[LARVOL @Larvol]

Top 100 Oncologists on Twitter. Click the link to download the spreadsheet. No signup necessary. https://t.co/vAd7QZHwqG

[Sina Vatandoust MD PhD @SVatandoust]

https://t.co/ThDZtEp5ci with the new #coronovirus in mind, most countries are not prepared for a pandemic

[Jeffrey Graham @DrJeffreyGraham]

Our analysis of clinical effectiveness of targeted therapy post-IO in mRCC. VEGFR-TKIs remain active, with improved outcomes compared to mTORI. @EurUrolOncol @DrDanielHeng @DrChoueiri @RIOH_Mb

https://t.co/OVWo0YYuam

[Dr Jennifer Bram @GoodFitMD]

What can men do ? #HeforShe

[Sina Vatandoust MD PhD @SVatandoust]

@SusanCarland Line of duty (Netflix)

[Hope Rugo @hoperugo]

Persistent risk of recurrence despite chemo in TailoRx high risk group - better than no chemo but a place for improvement. CDK4/6i? #ESMO2019

[Hope Rugo @hoperugo]

Dennis Slamon presents the survival data from monaleesa 3. Look at landmark analysis!! Great progress in the rx of HR+ MBC! #ESMO2019

[Sina Vatandoust MD PhD @SVatandoust]

@bogda_koczwara presenting on “cardiac considerations in #breast_cancer ” at #bct2019 . Great presentation, often overlooked in treating patients with #cancer

[Dr Sunil Verma @cancermd]

Great read- The Promise and Price of Cellular Therapies by ⁦@DrSidMukherjee⁩ https://t.co/098bvuiHhr

[Sina Vatandoust MD PhD @SVatandoust]

@MartinStockler @tmprowell @ASCO You did a great job presenting despite the cold 👍🏼

[Toni Choueiri, MD @DrChoueiri]

An absolutely epic presentation by @MejeanArnaud on the updated analysis of CARMENA:
Updated OS data, IMDC subgroups by number of RF, by number of met sites, and deferred CN.
CN may be especially beneficial in patients with 1 IMDC RF or when deferred!
#ASCO19 @ASCO #OncoAlert

[Sina Vatandoust MD PhD @SVatandoust]

Todays most important presentation :) #ASCO2019

[Mandy Davis Aitken @davisa20]

No better way to understand the size and scope of #asco19 than to watch the plenary session exit.

[Sina Vatandoust MD PhD @SVatandoust]

Fantastic presentation by @yzafar , truly practice changing concepts!

[Yousuf Zafar, MD MHS @yzafar]

I'm honored to discuss plenary LBA1, a study on healthcare access, equity, & real-world data--topics of global relevance

A non-traditional @ASCO plenary deserves a non-traditional approach so I'm live tweeting my talk thanks to @DukeGUCancer! #ASCO19 #ASCOhealthequity Pls share!

[Mark Lewis, MD, FASCO @marklewismd]

Landed in Chicago.

Opened email to find yet ANOTHER rejection.

Went to @artinstitutechi to cheer myself up before evening meetings at #asco19.

My manuscript is no masterpiece. But I started thinking: what if our greatest artists had faced the fearsome Reviewer #2?

THREAD/

[Tanya Dorff @TDorffOnc]

Powerful reminder to use bone support for mCRPC patients by Dr Tombal #ASCO19 from PRACE3 trial - we can prevent fractures!

[Sina Vatandoust MD PhD @SVatandoust]

Great discussions today from @Prof_IanD and scott williams #AusOnPodium #ASCO2019

[Sina Vatandoust MD PhD @SVatandoust]

Fantastic results from MONALEESA-7 (OS results). This is the first time that a CDK4/6 inhibitor or any targeted agent + ET has demonstrated significantly longer OS vs ET alone as initial endocrine-based therapy. #ASCO2019 #ASCO19 https://t.co/NaPHNY1lpv